Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021프라이밍, 부스팅 및 하이브리드 면역에 따른 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 항체 매개 면역원성: 이스라엘 의료 종사자 집단의 11개월 추적 관찰에서 얻은 통찰력, 2020년 12월-2021년 10월Article Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, [키워드] acute respiratory syndrome Against age all age group all age groups anti-S Antibody titer Breakthrough infection circulating Cohort comparable coronavirus coronavirus 2 coronavirus disease COVID-19 decrease described dose doses geometric mean concentration GMC HCW HCWs healthcare worker highlight hybrid IgG IgG level IgG levels IgG titer Immunity immunogenicity Immunoglobulin individual infected individual infected individuals Infection initial insight Israel Month participant PCR polymerase chain proportion Protective Quantitative re-infected Reinfection remained respiratory reversed S1/S2 SARS-CoV-2 subsequent tested timepoint uninfected vaccination Vaccine vaccine immunogenicity Vaccines waned worker [DOI] 10.1093/cid/ciac212 PMC 바로가기 [Article Type] Article
Routine SARS-CoV-2 vaccination for all children모든 어린이를 위한 정기 SARS-CoV-2 예방 접종Review Published on 2022-08-012022-09-11 Journal: Immunological reviews [Category] COVID19(2023년), SARS, 변종, [키워드] Adults benefit children children with COVID-19 COVID-19 death develop effective Efficacy Health Hospitalization infant immunity Infection Inflammatory knowledge less MIS-C Neonate Neonates Older pandemic Pathogenesis pediatric Population resulting routine SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 variant severe complications severe disease syndrome vaccine immunogenicity Vaccines virus [DOI] 10.1111/imr.13108 PMC 바로가기 [Article Type] Review
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trialCOVID-19 회복기 참가자에 대한 FINLAY-FR-1A 백신의 안전성 및 면역원성: 공개 라벨 2a상 및 이중 맹검, 무작위 배정, 위약 대조, 2b상, 심리스, 임상 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI adverse event All participants Alpha anti-RBD antibody assigned Asymptomatic Beta clinical clinical trial clinical trials Complete control group control groups convalescent convalescent individual convalescent individuals COVID-19 criteria Cuba defined delta variant Delta variants dimeric double-blind education elicited ELISA Endpoint enrolled Environment evaluate evaluated experimental group first stage geometric mean geometric mean titre geometric mean titres greater hematology ICTRP IgG antibodies immune response immunogenicity immunology increase in injected injection injection site Intervention intervention group Mild minor Moderate COVID-19 natural immunity Negative PCR neutralisation test neutralising antibody Occurrence Open-label Pain participant Participants PCR test per-protocol population Phase 1 Phase 2 Placebo placebo group placebo-controlled prevaccination Primary outcome Primary outcomes Public randomised Randomly Receptor binding domain recruited Registered registry reported Safety safety analysis safety population safety profile SARS-CoV-2 Science seamless secondary Secondary endpoints Serious Adverse Event Serious Adverse Events seroconversion rate sexual single dose stages study population technology the placebo group titre Trial two groups vaccination Vaccine vaccine immunogenicity Virus neutralisation Volunteer was done WHO-ICTRP [DOI] 10.1016/S2213-2600(22)00100-X PMC 바로가기 [Article Type] Clinical Trial
Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in JapanObservational Study Published on 2022-08-012022-10-05 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory syndrome adverse event Against Anti-spike antibody assumed Cancer conducted controls coronavirus coronavirus 2 COVID-19 Efficacy enrolled hospital Immune checkpoint inhibitor Immune checkpoint inhibitors Immune-related adverse event immunogenicity Immunoglobulin incidence interquartile range irAE irAEs Japan lung cancer median age mRNA mRNA vaccine multicenter observational study nine Patient postvaccination predicted primary end point respiratory risk Safety SARS-CoV-2 seroconverted Seven significantly lower the patient treated vaccination vaccination rate vaccine immunogenicity [DOI] 10.1016/j.jtho.2022.05.015 PMC 바로가기 [Article Type] Observational Study
Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant동종 골수 이식 후 2년 미만의 환자에서 1차 COVID-19 예방 접종에 대한 체액 및 세포 반응 손상Article Published on 2022-08-012022-09-11 Journal: British Journal of Haematology [Category] MERS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 adverse outcome adverse outcomes Allogeneic allogeneic bone marrow transplant analysed anti-S IgG Anti-spike BNT162b2 Bone marrow booster Cell Cell-mediated immunity cellular response ChAdOx1 Cohort coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) Coronavirus-2 COVID-19 COVID-19 vaccination Critical defined enzyme-linked immunospot Evidence evidence of haematopoietic stem cell transplant (HSCT) HCs healthy control high risk HSCT HSCT recipient HSCT recipients humoral IFNγ IgG Immunoglobulin Immunoglobulin G ImmunoSpot Impaired interferon less majority Patient Prophylactic prophylactic measure prophylactic measures rate of seroconversion recipient respiratory responders Seroconversion Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) significantly higher significantly lower stem cell T-cell T-cell Response T-cell responses These data titre Transplant vaccination schedule Vaccination strategy Vaccine vaccine immunogenicity Vaccines variants [DOI] 10.1111/bjh.18312 PMC 바로가기 [Article Type] Article
Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicityarticle Published on 2022-07-142024-09-02 Journal: Immunity & Ageing : I & A [Category] 대상포진, [키워드] aging Depression immunosenescence inflammaging Psychiatric disorders SARS CoV-2 vaccine immunogenicity [DOI] 10.1186/s12979-022-00288-7 PMC 바로가기 [Article Type] article
Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome원발성 항인지질 증후군 환자에서 SARS-CoV-2 백신 후 면역원성, 안전성 및 항인지질항체Article Published on 2022-07-012022-09-12 Journal: Lupus [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] adenovirus-based age anti-SARS-CoV-2 antibody antiphospholipid antibodies Antiphospholipid syndrome blood collection both group changes in Coagulopathy comparable complications control group coronavirus disease 19 COVID-19 event Evidence Frequency glycoprotein IgG IgM immunization immunogenicity inactivated increased risk naïve neutralizing antibody Participants Patient patients provided raised recent remained S1/S2 Safety safety profile SARS-CoV-2 SARS-CoV-2 vaccine second dose Seroconversion Sex Side effect syndrome thrombosis vaccination Vaccine vaccine immunogenicity virus [DOI] 10.1177/09612033221102073 PMC 바로가기 [Article Type] Article
COVID-19 and solid organ transplantation: Finding the right balanceReview article Published on 2022-07-012022-10-05 Journal: Transplantation Reviews [Category] COVID19(2023년), SARS, 치료제, [키워드] Acute kidney injury adjusted advanced age analyzed article articles association Cellular immune response clinical outcomes Comorbidity comparable concerning COVID-19 COVID-19 disease COVID-19 infection COVID-19 pandemic COVID-19 vaccination dysfunction Efficacy Factor finding higher risk humoral immune response Immunity Immunosuppression immunosuppressive include independent risk factor lung transplant Mortality mortality risk objective organ pandemic Patient recipient recipients reported Research Result risk factor Risk factors severe COVID-19 disease severe disease solid organ transplant solid organ transplantation SOT SOT patient systematic review therapy vaccination vaccine immunogenicity was performed [DOI] 10.1016/j.trre.2022.100710 [Article Type] Review article
Covid-19 vaccine immunogenicity in people living with HIV-1HIV-1에 감염된 사람들의 코비드-19 백신 면역원성Article Published on 2022-06-092022-09-12 Journal: Vaccine [Category] MERS, 임상, 진단, [키워드] age Analysis Anti-RBD IgG antibody baseline booster dose CD4 CD4 count CD4 counts clinical trial control group COVID-19 vaccine Covid-19 Vaccine immunogenicity Covid-19 Vaccines in Immunocompromised Patients Covid-19 Vaccines in people living with HIV effective Efficacy ELISA evaluated first dose General population Health care worker HIV HIV clinics HIV-1 HIV-positive individual HIV-positive individuals Hypothesis IgG response Immunocompromised patients Immunosuppression Increasing individual lowest Montreal mRNA mRNA vaccine mRNA vaccine immunogenicity in people living with HIV. mRNA Vaccines in people living with HIV naïve negative control participant receiving recruited response SARS CoV-2 second dose significantly lower stratified Support Vaccine vaccine immunogenicity Vaccine immunogenicity HIV was used were measured with HIV [DOI] 10.1016/j.vaccine.2022.04.090 PMC 바로가기 [Article Type] Article
Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients오크렐리주맙 치료를 받은 재발-완화성 다발성 경화증 환자에서 단일 SARS-COV-2 백신 투여 후 혈청전환 감소Article Published on 2022-06-012022-09-11 Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] 95% CI 95% confidence interval antibodies AZD1222 B-cell B-cells BNT162b2 CD20 COVID-19 COVID-19 vaccine detectable diminished dose Efficacy expected Humoral response IgG immunogenicity Immunoglobulin Immunoglobulin G individuals Luminex assay Ocrelizumab Odds ratio Patient patients predicted recipient recipients Relapsing-Remitting Multiple Sclerosis SARS-CoV-2 Seroconversion seroconverted single dose the patient undetectable vaccination Vaccine vaccine dose vaccine immunogenicity [DOI] 10.1177/13524585211046786 PMC 바로가기 [Article Type] Article